Fig. 1 · Structure

Documents & Downloads

Paricalcitol

Cat. No. A11533 CAS 131918-61-1
Paricalcitol is a drug used for the prevention and treatment of secondary hyperparathyroidism (excessive secretion of parathyroid hormone) associated with chronic renal failure.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
HL-60 EC50 12.5 nM Induction of human HL60 cell differentiation after 4 days by NBT reduction assay [PMID: 24035340]

Paricalcitol Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Paricalcitol from 3 published references. In vitro models include primary culture of pig parathyroid cells. In vivo models include female 2-month-old Wistar Kyoto rats.

Paricalcitol In Vitro Studies

Paricalcitol was evaluated in primary cultures of pig parathyroid cells treated for 24 hours against untreated controls. PTH mRNA decreased in a dose-dependent manner, achieving 75% inhibition at 100 nM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Paricalcitol Reduces PTH mRNA in Pig Parathyroid Cells

Cell-based study · primary culture of pig parathyroid cells [1]

Primary cultures of pig parathyroid cells were treated with Paricalcitol for 24 hours, with untreated cells as controls. Paricalcitol decreased PTH mRNA in a dose-dependent manner, achieving 75% inhibition at 100 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
PTH mRNA; real-time RT-PCRPTH mRNA 75% inhibition[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
24 hours
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: Paricalcitol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

3. Results (S58, S59); Figure 5 legend (S95, S98, S100)

PTH mRNA; real-time RT-PCR: PTH mRNA; real-time RT-PCR; comparator: control (no drug treatment) — 3. Results (S59)

Paricalcitol In Vivo Studies

In nephrectomized uremic rats receiving a hyperphosphatemia-inducing diet, Paricalcitol treatment yielded total serum calcium of 10.1 ± 0.27 mg/dL, with the compound effect assessed versus NX-vehicle. In rats with guidewire-induced endothelial injury, the intima/media ratio was 0.17 (0.07, 0.29) with Paricalcitol and 0.18 (0.11, 0.40) with Injury Vehicle. In mice with catheter implantation, peritoneal membranes were thicker in the PDF-treated group than in the Paricalcitol-treated group. [1,2,3]

Serum Calcium in Uremic Rats

Animal study · male, Sprague-Dawley rats; 5/6 nephrectomized (NX) uremic rats; n = 8–11 per group [1]

Male Sprague-Dawley nephrectomized uremic rats receiving a hyperphosphatemia-inducing diet were treated with Paricalcitol at 0.33 μg/kg i.p. Total serum calcium was 10.1 ± 0.27 mg/dL, with the compound effect assessed versus NX-vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total serum Ca (mg/dL)Total serum Ca 0.33 μg/kg, hyperphosphatemia-inducing diet: Total serum Ca (mg/dL), 10.1 ± 0.27[1]

Conditions shared by the study groups

Route
i.p.
Treatment course
3 times/week, for two weeks
Vehicle
5% ethanol +95% propylene glycol, 0.4 mL/kg
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Paricalcitol 0.33 μg/kg5/6 NX-vehicle10.1 ± 0.27 mg/dL; 8.99 ± 0.35 mg/dL; # P < .05 versus NX-vehicle[1]
Paricalcitol 0.33 μg/kg
Model: male, Sprague-Dawley rats; 5/6 nephrectomized (NX) uremic rats; n = 8–11 per group
Methods and source locations

Compound reported in the paper: Paricalcitol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Methods > 2.2. Subtotally Nephrectomized Rats (S3, S4, S5); 3. Results (S49, S54, S56); Figure 2 legend (S76); Figure 4 legend (S89); Table 1 legend (S110, S111); Table 1 (T1.h1, T1.r4)

Total serum Ca (mg/dL): Total serum Ca (mg/dL); comparator: 5/6 NX-vehicle — Figure 4 legend (S89); Table 1 legend (S110, S111); Table 1 (T1.h1, T1.r4)

Paricalcitol 0.33 μg/kg · Figure 4 legend (S89); Table 1 legend (S111); Table 1 (T1.h1, T1.r4)

Paricalcitol and Intima/Media Ratio After Vascular Injury

Animal study · female 2-month-old Wistar Kyoto rats [2]

Female Wistar Kyoto rats underwent endothelial denudation through guidewire injury and received Paricalcitol intraperitoneally at 750 ng/kg of body weight every other day. The intima/media ratio was 0.17 (0.07, 0.29) for Injury Paricalcitol versus 0.18 (0.11, 0.40) for Injury Vehicle, with a p value of 0.41.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Intima/media ratioIntima/media ratio 0.17 (0.07, 0.29)[2]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
every other day; starting immediately after the intervention for 2 weeks
Vehicle
alcohol 20% v/v, propylene glycol and purified water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Paricalcitol 750 ng/kg of body weightInjury VehicleInjury Paricalcitol: 0.17 (0.07, 0.29); Injury Vehicle: 0.18 (0.11, 0.40); p Value (Injury Paricalcitol vs. Injury Vehicle): 0.41[2]
Paricalcitol 750 ng/kg of body weight
Model: female 2-month-old Wistar Kyoto rats
Methods and source locations

Compound reported in the paper: Paricalcitol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.1. Paricalcitol, Intimal Hyperplasia and Stenosis Secondary to Endothelial Injury (S2); 4. Materials and Methods > 4.2. Animal Model (S24); Table 1 (T1.h1, T1.r2)

Intima/media ratio: Intima/media ratio; comparator: Injury Vehicle — Table 1 (T1.h1, T1.r2)

Paricalcitol 750 ng/kg of body weight · 4. Materials and Methods > 4.2. Animal Model (S24); Table 1 (T1.h1, T1.r2)

Peritoneal Membrane Thickness in Mice

Animal study · Female C57BL/6 mice; n = 11 [3]

Female mice with catheter implantation received Paricalcitol at 0.3 µg/kg/week, instilled daily into the peritoneal cavity for 30 days. Peritoneal membranes were thicker in the PDF-treated group than in the paricalcitol-treated group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
thickness of peritoneal membraneReported result At a dosage of 0.3 µg/kg/week (0.86 ng/mouse/day), instilled daily into the mouse peritoneal cavity for 30 days: thicker peritoneal membranes in the PDF-treated group as compared with the paricalcitol-treated group.[3]

Conditions shared by the study groups

Route
instilled daily into the mouse peritoneal cavity
Treatment course
daily into the mouse peritoneal cavity for 30 days
Vehicle
PDF
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Paricalcitol 0.3 µg/kg/week (0.86 ng/mouse/day)PDF group; n = 10At a dosage of 0.3 µg/kg/week (0.86 ng/mouse/day), instilled daily into the mouse peritoneal cavity for 30 days: thicker peritoneal membranes in the PDF-treated group as compared with the paricalcitol-treated group.[3]
Paricalcitol 0.3 µg/kg/week (0.86 ng/mouse/day)
Model: Female C57BL/6 mice; n = 11
Methods and source locations

Compound reported in the paper: Paricalcitol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Animals and surgery (S2, S3, S13, S14); Materials and Methods > Paricalcitol treatment (S19); Materials and Methods > Histological analyses and immunofluorescence (S22); Results > Paricalcitol treatment ameliorated peritoneal inflammation and fibrosis (S60, S62)

thickness of peritoneal membrane: thickness of peritoneal membrane; comparator: PDF group; n = 10 — Materials and Methods > Paricalcitol treatment (S19); Results > Paricalcitol treatment ameliorated peritoneal inflammation and fibrosis (S60, S62)

Paricalcitol 0.3 µg/kg/week (0.86 ng/mouse/day) · Materials and Methods > Paricalcitol treatment (S19); Results > Paricalcitol treatment ameliorated peritoneal inflammation and fibrosis (S62)

Specifications

Manufacturer Adooq Bioscience
CAS Number 131918-61-1
Formula C27H44O3
Molecular Weight 416.64
SMILES
CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 75 mg/mL (180.01 mM)
Water Insoluble
Ethanol 12 mg/mL (28.8 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Paricalcitol Research References

  1. [1] Wu-Wong JR, Nakane M, Gagne GD, et al. Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int J Endocrinol (2010). PMID: 20204178 DOI: 10.1155/2010/621687 Source material
  2. [2] Baeza C, Pintor-Chocano A, Carrasco S, et al. Paricalcitol Has a Potent Anti-Inflammatory Effect in Rat Endothelial Denudation-Induced Intimal Hyperplasia. Int J Mol Sci (2024). PMID: 38732029 DOI: 10.3390/ijms25094814 Source material
  3. [3] González-Mateo GT, Fernández-Míllara V, Bellón T, et al. Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production. PLoS One (2014). PMID: 25279459 DOI: 10.1371/journal.pone.0108477 Source material

Added to your cart

View Cart Checkout
Loading...